Estrella Immunopharma, Inc.
General ticker "ESLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $52.0M (TTM average)
Estrella Immunopharma, Inc. does not follow the US Stock Market performance with the rate: -13.9%.
Estimated limits based on current volatility of 4.3%: low 0.72$, high 0.78$
Factors to consider:
- Total employees count: 3 as of 2021
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Current price 28.4% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.03$, 2.66$]
- 2026-12-31 to 2027-12-31 estimated range: [0.85$, 2.26$]
Financial Metrics affecting the ESLA estimates:
- Positive: with PPE of -4.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.16 <= 0.30
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Shareholder equity ratio, % of -326.29 <= 19.10
Short-term ESLA quotes
Long-term ESLA plot with estimates
Financial data
| YTD | 2024-06-30 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $7.31MM | $8.85MM | $13.06MM |
| Operating Income | $-7.31MM | $-8.85MM | $-13.06MM |
| R&D Expense | $4.11MM | $6.41MM | $10.25MM |
| Income(Loss) | $-7.31MM | $-8.85MM | $-13.06MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-7.31MM | $-8.84MM | $-13.06MM |
| Stockholders Equity | $4.27MM | $0.14MM | $-10.37MM |
| Assets | $4.45MM | $3.14MM | $3.18MM |
| Operating Cash Flow | $-16.07MM | $-7.64MM | $-1.79MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $4.96MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $12.79MM | $-0.49MM | $2.25MM |
| Earnings Per Share** | $-0.21 | $-0.24 | $-0.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.